Contact us

Please complete the form below and a member of the AQUIPTA^®▼ (atogepant) team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to contact an AbbVie representative.

AQUIPTA^® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.¹

The AQUIPTA^® prescribing information and adverse event reporting information can be found at the bottom of the page.

First name:*

Please enter First name

Last name:*

Please enter Last name

Role:*

Please enter Role

E-mail address:*

E-mail address is not valid

Phone number:

Please enter Last name

Hospital name:

Please enter Hospital name

Hospital postcode:

Please enter hospital postcode

Areas of interest

Request a meeting with your local AbbVie representative

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗮𝗻 𝗮𝗽𝗽𝗼𝗶𝗻𝘁𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗮 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁

Please select a field.

I consent to receive AbbVie Ltd communications about its products, services, research, events, programmes and other information, including promotional content, that may be of interest to me, using the information I provide. I may withdraw my consent at any time.

Please select one field.

Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again.

Reference:

1. AQUIPTA^® UK Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed October 2023

AQUIPTA® PRESCRIBING INFORMATION

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk

Adverse events should also be reported to AbbVie on [email protected]

Date of preparation: October 2023. UK-ATP-230160.

Contact us

Our therapy areas

Additional info

This website is for UK Healthcare Professionals only

Welcome